

40년 전통의 Rx-제약 제조 사업





40 Rx-

매물로 나온 이 회사는 인도 방갈로르에 본사를 둔 헬스케어 회사입니다. 이 비즈니스는 전 세계 사람들에게 의약품 및 영양 보충제를 제조 및 공급하는 데 관여합니다(WHO-GMP 및 ISO 인증에서 지정한 품질 표준).

이 사업장은 ISO 9001 및 WHO GMP 인증을 받은 시설로 중앙 아메리카, 나이지리아, 방글라데시, 캄보디아, 스리랑카, 말레이시아, 도미니카 공화국 등의 국가에서 주문에 대응하고 있습니다. 이 시설은 정제, 캡슐 및 경구용 액체 생산 전용으로 50000평방피트 이상의 건축 면적을 보유하고 있습니다.

회사는 일반의약품, 건강기능식품 및 한약재를 생산합니다.

(3)

지난 3년 동안 매출은 꾸준히 증가했지만 상각전영업이익(EBITDA)은 감소했습니다. 5년 전에 시작된 온라인 브랜드의 광고비 지출 증가로 인해 EBITDA가 감소했습니다. 이 D2C 보충제 브랜드에서 발생한 모든 수익은 브랜드 마케팅에 다시 투입되고 있으며, 이는 회사 전체의 EBITDA 감소로 이어졌습니다.

438개의 일반 의약품 제조 라이선스. 이 중 현재 148개의 CoPP 승인을 획득하여 여러 ROW 국가에 제품을 수출할 수 있도록 등록했습니다.

소규모 제조 시설을 위한 높은 생산 능력과 비용 이점을 제공합니다. 방갈로르 시내에 위치한 제조 유닛에서는 숙련된 노동력과 비숙련 노동력을 모두 이용할 수 있습니다.

TARGET PRICE

\$12,000,000

GROSS REVENUE

\$1,900,000

EBITDA

\$0

BUSINESS TYPE

제약

ESTABLISHED

1982

SUPPORT & TRAINING

일년

REASON FOR SELLING

퇴직

COUNTRY

인도

BUSINESS ID

L#20210016

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

www.mergerscorp.com



© 2024 MergersCorp M&A International. All rights reserved.

© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.



WWW.MERGERSCORP.COM